Figure 3.

Reducing ARPC3 expression decreases the number of invasive tumor cells. (A) Western-blot of ARPC3 and Tubulin on BCBM tumor cells engineered with the shScramble or shARPC3 constructs. See Figure S1 for uncropped blot. (B) Representative images and (C) quantification of Ki67 immunohistochemistry staining in BCBM derived from shScramble or shARPC3 organoids intracranially injected into recipient mice. Data are presented as mean +/− standard-error of the mean (SEM); n = 5 mice per group; p-value was determined using a Mann–Whitney t-test, two-tailed. (D) Quantification of the number of invasive tumor cells observed by intravital imaging of ROSA26^mTmG mice injected with shScramble or shARPC3 BCBM organoids. Data are presented as mean +/− SEM; n = 4 mice for shScramble and n = 3 mice for shARPC3 #2; p-value was determined using a Mann–Whitney t-test, one-tailed. (E) Representative multi-photon images of BCBM derived from shScramble and shARPC3 BCBM organoids intracranially injected into ROSA26^mTmG mice.